TRANSLATIONAL ONCOLOGY PROGRAM

转化肿瘤学项目

• 批准号: 8740831
• 负责人: John P Fruehauf
• 金额: $ 1.91万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-11 至 2016-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8740831
• 关键词: Angiogenesis Inhibitors; Area; Breast; Breast Melanoma; Cancer Center Support Grant; Cervical; Chemoprevention; Clinical; Clinical Research; Clinical Trials; Collaborations; Comprehensive Cancer Center; Coupled; Development; Disease; Funding; Goals; Growth; Journals; Link; Malignant Neoplasms; Mission; Neoadjuvant Therapy; Outcome; Peer Review; Pharmacologic Substance; Phase; Prognostic Marker; Prostate; Publications; Publishing; Reactive Oxygen Species; Research Personnel; Resources; Schools; Scientist; Signal Pathway; Signal Transduction; Translating; University of California Irvine Cancer Center; cancer care; clinical application; improved; member; novel; novel strategies; novel therapeutic intervention; oncology program; programs; working group

The Translational Oncology (TO) Program's mission is to develop clinical trials that promote interaction between basic scientists, translational scientists, and clinicians to facilitate improved clinical outcomes. During the last review period the Program was organized into the following three thematic areas that are emphasized in disease-specific working groups: (1) Develop and carry out early phase clinical trials with a goal to translate findings into the cooperative group or phase III setting; (2) Facilitate inclusion of predictive and prognostic biomarker profiles in clinical trials; (3) Develop novel therapeutic approaches related to antiangiogenesis agents, signaling pathways and reactive oxygen species (ROS). In order to promote interprogrammatic and intra-programmatic interactions and translational activities, disease specific translational working groups (TWGs) were recently established for melanoma, breast, Gl, prostate and cervical/GYN cancers. Clinical trials coupled to translational endpoints have been developed through inter-programmatic collaborations with other Programs, including Oncoimaging (Neoadjuvant breast), and Cacinogenesis and Signaling (CML, prostate). Over the past five years, our Program has focused on accrual to clinical research trials, including Hypothesis-driven, investigator-initiated trials (HDII), cooperative group, and pharmaceutical sponsored trials. Emphasis has been placed on HDII trials to exploit UCI's rich Comprehensive Cancer Center resources to develop novel approaches to cancer care. HDII accrual over the past six years has grown dramatically from 60 in 2002-2004 to 175 in 2005-2007. Overall interventional clinical trials accrual, excluding chemoprevention trials, was 142 in 2002-2003, increasing to 218 in 2004-2005, and 387 to date in 2005-2007, Of particular significance, this growth in accrual was linked to translational endpoints that led to peer reviewed funding and increased numbers of publications in high impact journals. The TO Program has 25 Members, representing eight Departments and one School, and has $2,024,203 in direct cancer-related peer-reviewed funding, 10 projects of which are funded by NCI for a direct total of $1,187,498. In 2007, Members published a total of 71 publications with 62 of those being cancer-related of which 44% were inter- and 16% were intra-related.

转化肿瘤学 (TO) 计划的使命是开展临床试验，促进基础科学家、转化科学家和临床医生之间的互动，以促进改善临床结果。在上一次审查期间，该计划分为以下三个主题领域，这些领域是特定疾病工作组所强调的： (1) 开发和开展早期临床试验，目标是将研究结果转化为合作组或 III 期环境； (2) 促进将预测和预后生物标志物概况纳入临床试验； (3) 开发与抗血管生成剂、信号通路和活性氧（ROS）相关的新治疗方法。为了促进程序间和程序内的相互作用和转化活动，最近针对黑色素瘤、乳腺癌、GI、前列腺癌和宫颈癌/妇科癌症建立了疾病特异性转化工作组（TWG）。与转化终点相结合的临床试验是通过与其他项目的跨项目合作开发的，包括肿瘤成像（新辅助乳腺癌）和癌发生和信号传导（CML、前列腺）。在过去的五年中，我们的计划重点关注临床研究试验的应计进展，包括假设驱动、研究者发起的试验 (HDII)、合作小组和药物赞助的试验。 HDII 试验的重点是利用 UCI 丰富的综合癌症中心资源来开发新的癌症治疗方法。过去六年中 HDII 的增长已从 2002-2004 年的 60 大幅增长到 2005-2007 年的 175。总体介入临床试验（不包括化学预防试验）在 2002-2003 年为 142 项，在 2004-2005 年增加到 218 项，在 2005-2007 年迄今为 387 项。特别重要的是，应计项目的增长与转化终点相关，从而导致同行评审资金和高影响力期刊中出版物数量的增加。 TO 计划有 25 名成员，代表 8 个部门和 1 个学院，拥有 2,024,203 美元的癌症相关同行评审直接资助，其中 10 个项目由 NCI 资助，直接资助总额为 1,187,498 美元。 2007年，会员共发表了71篇出版物，其中62篇与癌症相关，其中44%为相互相关，16%为内部相关。